4,857 views
Vortioxetine (Brintellix in Italy), according to official notes, should be an innovative antidepressant (defined as "multimodal") because it not only raises serotonin levels like almost all other antidepressants (through the inhibition of the reuptake of this neurotransmitter) but is also able to modulate (i.e. inhibit and/or excite) some serotonin receptors (including mainly 5HT1A, 5HT1B, 5HT3 and 5HT7) which would contribute to its antidepressant power. However, the reality that emerges after about 10 years from the first marketing of the product, is instead very different: Vortioxetine (Brintellix) seems to give relief from depression and anxiety only in a very low percentage of cases. In my clinical experience, I have only known two patients who report having benefited from Vortioxetine, out of a total of hundreds who have taken it for anxiety and/or depression, waiting and suffering even for many months, hoping for an effect that never came. What amazes me most is that there are still so many doctors, even psychiatric specialists, who continue to prescribe it as if it were the Ferrari of antidepressants and this is perhaps only because it is the newest or because the marketing campaign has been particularly widespread and successful.